Should You Investigate RxSight, Inc. (NASDAQ:RXST) At US$52.84?
RxSight, Inc. to Report First Quarter Financial Results on May 6, 2024
ALISO VIEJO, Calif., April 22, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery,
Companies Like RxSight (NASDAQ:RXST) Can Afford To Invest In Growth
We can readily understand why investors are attracted to unprofitable companies. Indeed, RxSight (NASDAQ:RXST) stock is up 197% in the last year, providing strong gains for shareholders. But while
Needham Sees BSX, CNMD, RMD Beating Street, Despite Medtech Slow Down
Assessing RxSight: Insights From 8 Financial Analysts
RxSight (NASDAQ:RXST) underwent analysis by 8 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.Summarizing their recent assessments, the table below illustrates
Needham: Reiterated the RxSight (RXST.US) rating, adjusted from buy to buy rating, target price $64.00.
Needham: Reiterated the RxSight (RXST.US) rating, adjusted from buy to buy rating, target price $64.00.
Needham Reiterates Buy on RxSight, Maintains $64 Price Target
Needham analyst David Saxon reiterates RxSight with a Buy and maintains $64 price target.
Analysts Have Conflicting Sentiments on These Healthcare Companies: Abivax SA Sponsored ADR (ABVX), RxSight (RXST) and Clearside Biomedical (CLSD)
RxSight Announces Commercial Launch of Its Newest Light Adjustable Lens, the LAL+, and Features Multiple Doctor Presentations at the Upcoming ASCRS Annual Meeting
ALISO VIEJO, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery,
RxSight(RXST.US) Officer Sells US$997.95K in Common Stock
$RxSight(RXST.US)$ Officer Thunen Shelley B sold 20,000 shares of Common Stock on Apr 1, 2024 at an average price of $49.8973 for a total value of $997.95K.Source: Announcement What is statement of ch
Rxsight Insider Sold Shares Worth $997,946, According to a Recent SEC Filing
Shelley B Thunen, Chief Financial Officer, on April 01, 2024, sold 20,000 shares in Rxsight (RXST) for $997,946. Following the Form 4 filing with the SEC, Thunen has control over a total of 22,093 sha
Form 144 | RxSight(RXST.US) Officer Proposes to Sell 996.33K in Common Stocks
SEC FILLINGS DISCLOSED/ Apr 1, $RxSight(RXST.US)$ Officer Thunen Shelley B intends to sell 20,000 shares of its common stock on Apr 1, with a total market value of approximately $996.33K. Source: A
RxSight, Inc. to Participate in the 23rd Annual Needham Virtual Healthcare Conference
ALISO VIEJO, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery,
Is RxSight, Inc. (NASDAQ:RXST) Potentially Undervalued?
While RxSight, Inc. (NASDAQ:RXST) might not have the largest market cap around , it led the NASDAQGM gainers with a relatively large price hike in the past couple of weeks. The company is inchin
RxSight(RXST.US) Officer Sells US$563.73K in Common Stocks
$RxSight(RXST.US)$ Officer Thunen Shelley B sold 10,000 shares of Common Stocks on Mar 1, 2024 at an average price of $56.3726 for a total value of $563.73K.Source: Announcement What is statement of c
Patrick Wood Reaffirms Buy Rating for RxSight Amid Strong Growth and Market Expansion Potential
RxSight, Inc. (NASDAQ:RXST) Released Earnings Last Week And Analysts Lifted Their Price Target To US$57.75
Earnings Call: RxSight Reported an Increase in Revenue of 78% in Q4
RxSight, Inc. to Participate in the 34th Annual Oppenheimer Healthcare Conference
ALISO VIEJO, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery,
RxSight Shares Target Raised to $64 on Strong Growth Outlook
No Data